NASDAQ:TRHC

Tabula Rasa HealthCare Stock Forecast, Price & News

$30.67
+0.47 (+1.56 %)
(As of 09/22/2021 04:00 PM ET)
Add
Compare
Today's Range
$30.13
$31.28
50-Day Range
$28.79
$46.84
52-Week Range
$27.01
$69.31
Volume229,323 shs
Average Volume314,336 shs
Market Capitalization$761.93 million
P/E RatioN/A
Dividend YieldN/A
Beta0.9
30 days | 90 days | 365 days | Advanced Chart
Receive TRHC News and Ratings via Email

Sign-up to receive the latest news and ratings for Tabula Rasa HealthCare and its competitors with MarketBeat's FREE daily newsletter.


Tabula Rasa HealthCare logo

About Tabula Rasa HealthCare

Tabula Rasa Healthcare, Inc. is a healthcare technology company, which engages in the development of solutions designed for pharmacists, providers, and patients to optimize medication regimens. It operates through the following segments: CareVention HealthCare and MedWise HealthCare. The CareVention HealthCare segment provides services, PACE, which is a center for Medicare & Medicaid services, or CMS, sponsored program providing medical and social services. Its brands include CareKinesis, Capstone Risk Adjustment Services, PACElogic, TruChart, PeakTPA, PersonifilRx, and Pharmastar. The MedWise HealthCare segment provides Medication Therapy Management, or MTM, software and services for Medicare, Medicaid, and commercial health plans, and also provides a cloud-based patient engagement software and services. It offers cloud-based software and clinical pharmacist services through its brands, including MedWise, SinfoníaRx, RxCompanion, PrescribeWellness, and DoseMeRx. The company was founded by Calvin H. Knowlton, Orsula V. Knowlton, and Michael Greenhalgh in April 2009 and is headquartered in Moorestown, NJ.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

2.31 out of 5 stars

Medical Sector

237th out of 1,352 stocks

Business Services, Not Elsewhere Classified Industry

32nd out of 134 stocks

Analyst Opinion: 3.2Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Tabula Rasa HealthCare (NASDAQ:TRHC) Frequently Asked Questions

Is Tabula Rasa HealthCare a buy right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tabula Rasa HealthCare in the last twelve months. There are currently 5 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Tabula Rasa HealthCare stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TRHC, but not buy additional shares or sell existing shares.
View analyst ratings for Tabula Rasa HealthCare
or view top-rated stocks.

What stocks does MarketBeat like better than Tabula Rasa HealthCare?

Wall Street analysts have given Tabula Rasa HealthCare a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Tabula Rasa HealthCare wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Tabula Rasa HealthCare's next earnings date?

Tabula Rasa HealthCare is scheduled to release its next quarterly earnings announcement on Tuesday, November 2nd 2021.
View our earnings forecast for Tabula Rasa HealthCare
.

How were Tabula Rasa HealthCare's earnings last quarter?

Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC) released its earnings results on Thursday, August, 5th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.35) by $0.19. The business earned $82.31 million during the quarter, compared to the consensus estimate of $81.49 million. Tabula Rasa HealthCare had a negative net margin of 30.27% and a negative trailing twelve-month return on equity of 34.79%.
View Tabula Rasa HealthCare's earnings history
.

How has Tabula Rasa HealthCare's stock been impacted by Coronavirus?

Tabula Rasa HealthCare's stock was trading at $45.88 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, TRHC stock has decreased by 33.2% and is now trading at $30.67.
View which stocks have been most impacted by COVID-19
.

What guidance has Tabula Rasa HealthCare issued on next quarter's earnings?

Tabula Rasa HealthCare issued an update on its FY 2021 earnings guidance on Thursday, September, 2nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $336 million-$356 million, compared to the consensus revenue estimate of $343.29 million.

What price target have analysts set for TRHC?

8 Wall Street analysts have issued 12-month price targets for Tabula Rasa HealthCare's shares. Their forecasts range from $40.00 to $55.00. On average, they anticipate Tabula Rasa HealthCare's stock price to reach $48.03 in the next twelve months. This suggests a possible upside of 56.6% from the stock's current price.
View analysts' price targets for Tabula Rasa HealthCare
or view top-rated stocks among Wall Street analysts.

Who are Tabula Rasa HealthCare's key executives?

Tabula Rasa HealthCare's management team includes the following people:
  • Calvin H. Knowlton, Chairman & Chief Executive Officer
  • Orsula V. Knowlton, President, Director & Chief Marketing Officer
  • Michael Greenhalgh, Chief Operating Officer (LinkedIn Profile)
  • Brian W. Adams, Chief Financial Officer & Secretary
  • Joseph J. Filippoli, Chief Information Officer

What is Calvin H. Knowlton, BScPharm, MDiv, PhD's approval rating as Tabula Rasa HealthCare's CEO?

24 employees have rated Tabula Rasa HealthCare CEO Calvin H. Knowlton, BScPharm, MDiv, PhD on Glassdoor.com. Calvin H. Knowlton, BScPharm, MDiv, PhD has an approval rating of 91% among Tabula Rasa HealthCare's employees. This puts Calvin H. Knowlton, BScPharm, MDiv, PhD in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Tabula Rasa HealthCare's key competitors?

What other stocks do shareholders of Tabula Rasa HealthCare own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tabula Rasa HealthCare investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), QUALCOMM (QCOM), Adobe (ADBE), Micron Technology (MU), (CGC), The Boeing (BA), salesforce.com (CRM), Intel (INTC) and Netflix (NFLX).

When did Tabula Rasa HealthCare IPO?

(TRHC) raised $60 million in an IPO on Thursday, September 29th 2016. The company issued 4,300,000 shares at a price of $13.00-$15.00 per share. Wells Fargo Securities, UBS Investment Bank and Piper Jaffray acted as the underwriters for the IPO and Baird and Stifel were co-managers.

What is Tabula Rasa HealthCare's stock symbol?

Tabula Rasa HealthCare trades on the NASDAQ under the ticker symbol "TRHC."

Who are Tabula Rasa HealthCare's major shareholders?

Tabula Rasa HealthCare's stock is owned by many different retail and institutional investors. Top institutional shareholders include Macquarie Group Ltd. (10.67%), Vanguard Group Inc. (6.06%), Geneva Capital Management LLC (4.34%), Baillie Gifford & Co. (4.25%), Credit Suisse AG (3.93%) and Bank of America Corp DE (3.75%). Company insiders that own Tabula Rasa HealthCare stock include Andrea Carolan Speers, Brian W Adams, Calvin H Knowlton, Dennis Helling, Gordon Tunstall, Michael Greenhalgh, Orsula V Knowlton and Samira Beckwith.
View institutional ownership trends for Tabula Rasa HealthCare
.

Which major investors are selling Tabula Rasa HealthCare stock?

TRHC stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Wasatch Advisors Inc., Credit Suisse AG, First Trust Advisors LP, Parallax Volatility Advisers L.P., Royal Bank of Canada, Legal & General Group Plc, and Bank of America Corp DE. Company insiders that have sold Tabula Rasa HealthCare company stock in the last year include Andrea Carolan Speers, Brian W Adams, Calvin H Knowlton, Gordon Tunstall, Michael Greenhalgh, and Orsula V Knowlton.
View insider buying and selling activity for Tabula Rasa HealthCare
or view top insider-selling stocks.

Which major investors are buying Tabula Rasa HealthCare stock?

TRHC stock was acquired by a variety of institutional investors in the last quarter, including Macquarie Group Ltd., Millennium Management LLC, Vanguard Group Inc., Millrace Asset Group Inc., Baillie Gifford & Co., Dimensional Fund Advisors LP, State Street Corp, and Artemis Investment Management LLP.
View insider buying and selling activity for Tabula Rasa HealthCare
or or view top insider-buying stocks.

How do I buy shares of Tabula Rasa HealthCare?

Shares of TRHC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Tabula Rasa HealthCare's stock price today?

One share of TRHC stock can currently be purchased for approximately $30.67.

How much money does Tabula Rasa HealthCare make?

Tabula Rasa HealthCare has a market capitalization of $761.93 million and generates $297.22 million in revenue each year. The company earns $-80,970,000.00 in net income (profit) each year or ($1.18) on an earnings per share basis.

How many employees does Tabula Rasa HealthCare have?

Tabula Rasa HealthCare employs 1,614 workers across the globe.

What is Tabula Rasa HealthCare's official website?

The official website for Tabula Rasa HealthCare is www.tabularasahealthcare.com.

Where are Tabula Rasa HealthCare's headquarters?

Tabula Rasa HealthCare is headquartered at 228 STRAWBRIDGE DRIVE SUITE 100, MOORESTOWN NJ, 08057.

How can I contact Tabula Rasa HealthCare?

Tabula Rasa HealthCare's mailing address is 228 STRAWBRIDGE DRIVE SUITE 100, MOORESTOWN NJ, 08057. The company can be reached via phone at (866) 648-2767 or via email at [email protected].


This page was last updated on 9/23/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.